FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2901801630> ?p ?o ?g. }

• W2901801630 endingPage "e13169" @default.
• W2901801630 startingPage "e13169" @default.
• W2901801630 abstract "Abstract Background: While liposomal cisplatin has shown enhanced drug tolerability and higher targeting property as compared with the conventional cisplatin, the doubt remains whether lipoplatin could improve its anticancer efficacy. What's more, there is still no systematic evaluation of the safety profiles of lipoplatin comparing with original cisplatin. Thus, we performed a systematic literature search for randomized clinical trials directly comparing efficacy and safety of liposomal cisplatin versus its conventional nonliposomal cisplatin. Methods: The electronic search was conducted in PubMed, Embase, The Cochrane Library, and ClinicalTrials.gov from inception to February 10, 2018. The pooled odds ratio (OR) and 95% confidence intervals (CIs) of progressive disease (PD), partial response (PR), stable disease (SD), and adverse events (AEs) were obtained to assess the efficacy and safety. Heterogeneity was estimated using the I 2 test ( I 2 > 50%, significant heterogeneity). Results: The search yielded 5 clinical trials that meet inclusion criteria, with a total of 523 patients. We found that the liposome encapsulated cisplatin was more clinical efficacious than cisplatin as assessed by PD rate (OR, 0.46; 95% CI, 0.28–0.74; P = .002), while subgroup analysis of the only nonsmall cell lung cancer (NSCLC) patients showed higher response rates in PR (OR, 0.46; 95% CI, 0.28–0.74; P = .002) and PD (OR, 0.46; 95% CI, 0.28–0.74; P = .002) simultaneously. In addition, the toxicity meta-analysis revealed lipoplatin was much less toxic than the original cisplatin, with respect to grade 3 to 4 neurotoxicity (OR, 0.18; 95% CI, 0.04–0.74; P = .02), grade 3 to 4 leukopenia (OR, 0.47; 95% CI, 0.26–0.85; P = .01), grade 3 to 4 neutropenia (OR, 0.26; 95% CI, 0.09–0.71; P = .009), grade 1 and 2 nausea/vomiting (OR, 0.50; 95% CI, 0.32–0.77; P = .002), and grade 3 and 4 asthenia (OR, 0.11; 95% CI, 0.03–0.42; P = .001). Conclusions: This meta-analysis revealed that with both NSCLC and squamous cell carcinoma of the head and neck (SCCHN) patients, liposomal cisplatin-based chemotherapy offers significant advantages regarding the PD and reduced toxicities relative to conventional cisplatin." @default.
• W2901801630 created "2018-11-29" @default.
• W2901801630 creator A5016439097 @default.
• W2901801630 creator A5065418781 @default.
• W2901801630 creator A5076733945 @default.
• W2901801630 creator A5082499111 @default.
• W2901801630 creator A5087149945 @default.
• W2901801630 date "2018-11-01" @default.
• W2901801630 modified "2023-09-26" @default.
• W2901801630 title "Meta-analysis of clinical trials comparing the efficacy and safety of liposomal cisplatin versus conventional nonliposomal cisplatin in nonsmall cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)" @default.
• W2901801630 cites W1963654724 @default.
• W2901801630 cites W1975429911 @default.
• W2901801630 cites W2000624161 @default.
• W2901801630 cites W2009038500 @default.
• W2901801630 cites W2016219766 @default.
• W2901801630 cites W2018001685 @default.
• W2901801630 cites W2019816153 @default.
• W2901801630 cites W2044159336 @default.
• W2901801630 cites W2055038373 @default.
• W2901801630 cites W2104550697 @default.
• W2901801630 cites W2168127523 @default.
• W2901801630 cites W2211149802 @default.
• W2901801630 cites W2340906166 @default.
• W2901801630 cites W2607735543 @default.
• W2901801630 cites W2728909854 @default.
• W2901801630 doi "https://doi.org/10.1097/md.0000000000013169" @default.
• W2901801630 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6257614" @default.
• W2901801630 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30431590" @default.
• W2901801630 hasPublicationYear "2018" @default.
• W2901801630 type Work @default.
• W2901801630 sameAs 2901801630 @default.
• W2901801630 citedByCount "19" @default.
• W2901801630 countsByYear W29018016302019 @default.
• W2901801630 countsByYear W29018016302020 @default.
• W2901801630 countsByYear W29018016302021 @default.
• W2901801630 countsByYear W29018016302022 @default.
• W2901801630 countsByYear W29018016302023 @default.
• W2901801630 crossrefType "journal-article" @default.
• W2901801630 hasAuthorship W2901801630A5016439097 @default.
• W2901801630 hasAuthorship W2901801630A5065418781 @default.
• W2901801630 hasAuthorship W2901801630A5076733945 @default.
• W2901801630 hasAuthorship W2901801630A5082499111 @default.
• W2901801630 hasAuthorship W2901801630A5087149945 @default.
• W2901801630 hasBestOaLocation W29018016301 @default.
• W2901801630 hasConcept C121608353 @default.
• W2901801630 hasConcept C126322002 @default.
• W2901801630 hasConcept C143998085 @default.
• W2901801630 hasConcept C156957248 @default.
• W2901801630 hasConcept C197934379 @default.
• W2901801630 hasConcept C2776256026 @default.
• W2901801630 hasConcept C2776530083 @default.
• W2901801630 hasConcept C2776694085 @default.
• W2901801630 hasConcept C2776833033 @default.
• W2901801630 hasConcept C2778239845 @default.
• W2901801630 hasConcept C2778375690 @default.
• W2901801630 hasConcept C535046627 @default.
• W2901801630 hasConcept C71924100 @default.
• W2901801630 hasConcept C95190672 @default.
• W2901801630 hasConceptScore W2901801630C121608353 @default.
• W2901801630 hasConceptScore W2901801630C126322002 @default.
• W2901801630 hasConceptScore W2901801630C143998085 @default.
• W2901801630 hasConceptScore W2901801630C156957248 @default.
• W2901801630 hasConceptScore W2901801630C197934379 @default.
• W2901801630 hasConceptScore W2901801630C2776256026 @default.
• W2901801630 hasConceptScore W2901801630C2776530083 @default.
• W2901801630 hasConceptScore W2901801630C2776694085 @default.
• W2901801630 hasConceptScore W2901801630C2776833033 @default.
• W2901801630 hasConceptScore W2901801630C2778239845 @default.
• W2901801630 hasConceptScore W2901801630C2778375690 @default.
• W2901801630 hasConceptScore W2901801630C535046627 @default.
• W2901801630 hasConceptScore W2901801630C71924100 @default.
• W2901801630 hasConceptScore W2901801630C95190672 @default.
• W2901801630 hasIssue "46" @default.
• W2901801630 hasLocation W29018016301 @default.
• W2901801630 hasLocation W29018016302 @default.
• W2901801630 hasLocation W29018016303 @default.
• W2901801630 hasLocation W29018016304 @default.
• W2901801630 hasOpenAccess W2901801630 @default.
• W2901801630 hasPrimaryLocation W29018016301 @default.
• W2901801630 hasRelatedWork W1998407477 @default.
• W2901801630 hasRelatedWork W2033451938 @default.
• W2901801630 hasRelatedWork W2500842884 @default.
• W2901801630 hasRelatedWork W2755967017 @default.
• W2901801630 hasRelatedWork W2808175591 @default.
• W2901801630 hasRelatedWork W3012537123 @default.
• W2901801630 hasRelatedWork W3150178349 @default.
• W2901801630 hasRelatedWork W3153102530 @default.
• W2901801630 hasRelatedWork W3170240527 @default.
• W2901801630 hasRelatedWork W363598932 @default.
• W2901801630 hasVolume "97" @default.
• W2901801630 isParatext "false" @default.
• W2901801630 isRetracted "false" @default.
• W2901801630 magId "2901801630" @default.
• W2901801630 workType "article" @default.